One of the Chief Investigator for Foxfire is Professor Ricky Sharma
https://www.ucl.ac.uk/cancer/resear...iation-oncology/research-profile-ricky-sharma
Professor Ricky Sharma is Chair of Radiation Oncology at University College London and a Scientific Group Leader at the UCL Cancer Institute. He is also an Honorary Consultant in Clinical Oncology at University College London Hospitals and the Royal Free Hospital, where he has a clinical practice in radiotherapy and chemotherapy. He graduated in medicine from the University of Cambridge, United Kingdom. He trained in general internal medicine, medical oncology and radiation oncology and completed a PhD on DNA damage repair. Ricky Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy.
The other Chief Investigator is Dr Harpreet Wasan
https://www.bmihealthcare.co.uk/consultants/harpreet-wasan
Dr Harpreet Wasan leads the gastrointestinal clinical research programme at Hammersmith Hospital, Imperial College London. He is on the UK National Cancer Research Institute steering committee of both the advanced colorectal cancer and upper gastrointestinal groups, as well as the inaugural chair of the West London Cancer Network.
Dr Wasan is involved in the Trial management of many CRC studies including one of the largest metastatic colorectal cancer studies in the world (COIN study), and the chief investigator (CI) in its sub-study (COIN-B), as well as a co-investigator on the largest prospective study in chemotherapy in the elderly (FOCUS-2) which reports in 2007. He is on the European working party on CRC liver metastases guidance.
In upper gastrointestinal cancer he is Co-PI and PI in the UK NRCN trials portfolio in advanced Biliary cancer and Cancer of unknown primary, with the latter two designed to be the largest studies of their kind in the world. He is a fellow of the Royal College of Physicians and the Oncology advisor to the UK Drugs and Therapeutics Bulletin (DTB) amongst many other national consultative roles.
- Forums
- ASX - By Stock
- SRX
- Ann: Investigation of Concerns around CEO Share Trading
Ann: Investigation of Concerns around CEO Share Trading, page-96
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $132.6K | 758.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 449688 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 955405 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 449688 | 0.175 |
5 | 1608822 | 0.170 |
1 | 18186 | 0.165 |
1 | 2577 | 0.097 |
1 | 4000 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 945405 | 26 |
0.185 | 38427 | 3 |
0.190 | 220025 | 8 |
0.195 | 20478 | 2 |
0.200 | 181416 | 6 |
Last trade - 15.47pm 30/08/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online